<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23306584</article-id><article-id pub-id-type="pmc">3625408</article-id><article-id pub-id-type="publisher-id">2787</article-id><article-id pub-id-type="doi">10.1007/s00134-012-2787-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Lower tidal volume strategy (&#x02248;3&#x000a0;ml/kg) combined with extracorporeal CO<sub>2</sub> removal versus &#x02018;conventional&#x02019; protective ventilation (6&#x000a0;ml/kg) in severe ARDS</article-title><subtitle>The prospective randomized Xtravent-study</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bein</surname><given-names>Thomas</given-names></name><address><email>thomas.bein@klinik.uni-regensburg.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Weber-Carstens</surname><given-names>Steffen</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Goldmann</surname><given-names>Anton</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Staudinger</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Brederlau</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Muellenbach</surname><given-names>Ralf</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Dembinski</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Graf</surname><given-names>Bernhard M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wewalka</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Philipp</surname><given-names>Alois</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Wernecke</surname><given-names>Klaus-Dieter</given-names></name><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Lubnow</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Slutsky</surname><given-names>Arthur S.</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><aff id="Aff1"><label/>Department of Anesthesia and Operative Intensive Care, Regensburg University Hospital, Regensburg, Germany </aff><aff id="Aff2"><label/>Department of Anesthesia and Operative Intensive Care Medicine, Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, Campus Virchow-Klinikum and Campus Charit&#x000e9; Mitte, Berlin, Germany </aff><aff id="Aff3"><label/>Department of Internal Medicine II, Regensburg University Hospital, Regensburg, Germany </aff><aff id="Aff4"><label/>Intensive Care Unit, Department of Internal Medicine I, Vienna General Hospital, Medical University of Vienna, Vienna, Austria </aff><aff id="Aff5"><label/>Department of Intensive Care Medicine, HELIOS Klinikum Berlin-Buch, Berlin, Germany </aff><aff id="Aff6"><label/>Department of Anaesthesia and Critical Care, University of W&#x000fc;rzburg, W&#x000fc;rzburg, Germany </aff><aff id="Aff7"><label/>Department of Intensive Care, University Hospital Aachen, RWTH Aachen University, Aachen, Germany </aff><aff id="Aff8"><label/>Intensive Care Unit, Division of Gastroenterology, Department of Internal Medicine III, Vienna General Hospital, Medical University of Vienna, Vienna, Austria </aff><aff id="Aff9"><label/>Department of Cardiothoracic Surgery, Regensburg University Hospital, Regensburg, Germany </aff><aff id="Aff10"><label/>Interdepartmental Division of Critical Care Medicine, Department of Medicine, Keenan Research Center at the Li Ka Shing Knowledge Institute of St. Michael&#x02019;s Hospital, University of Toronto, Toronto, Canada </aff><aff id="Aff11"><label/>SOSTANA GmbH, Biometric Statistical Analyses, Berlin, Germany </aff><aff id="Aff12"><label/>Department of Anesthesia and Critical Care, Regensburg University Hospital, 93042 Regensburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2013</year></pub-date><volume>39</volume><issue>5</issue><fpage>847</fpage><lpage>856</lpage><history><date date-type="received"><day>12</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Acute respiratory distress syndrome is characterized by damage to the lung caused by various insults, including ventilation itself, and tidal hyperinflation can lead to ventilator induced lung injury (VILI). We investigated the effects of a low tidal volume (<italic>V</italic><sub>T</sub>) strategy (<italic>V</italic><sub>T</sub>&#x000a0;&#x02248;&#x000a0;3&#x000a0;ml/kg/predicted body weight [PBW]) using pumpless extracorporeal lung assist in established ARDS.</p></sec><sec><title>Methods</title><p>Seventy-nine patients were enrolled after a &#x02018;stabilization period&#x02019; (24&#x000a0;h with optimized therapy and high PEEP). They were randomly assigned to receive a low <italic>V</italic><sub>T</sub> ventilation (&#x02248;3&#x000a0;ml/kg) combined with extracorporeal CO<sub>2</sub> elimination, or to a ARDSNet strategy (&#x02248;6&#x000a0;ml/kg) without the extracorporeal device. The primary outcome was the 28-days and 60-days ventilator-free days (VFD). Secondary outcome parameters were respiratory mechanics, gas exchange, analgesic/sedation use, complications and hospital mortality.</p></sec><sec><title>Results</title><p>Ventilation with very low <italic>V</italic><sub>T</sub>&#x02019;s was easy to implement with extracorporeal CO<sub>2</sub>-removal. VFD&#x02019;s within 60&#x000a0;days were not different between the study group (33.2&#x000a0;&#x000b1;&#x000a0;20) and the control group (29.2&#x000a0;&#x000b1;&#x000a0;21, <italic>p</italic>&#x000a0;=&#x000a0;0.469), but in more hypoxemic patients (PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;150) a post hoc analysis demonstrated significant improved VFD-60 in study patients (40.9&#x000a0;&#x000b1;&#x000a0;12.8) compared to control (28.2&#x000a0;&#x000b1;&#x000a0;16.4, <italic>p</italic>&#x000a0;=&#x000a0;0.033). The mortality rate was low (16.5&#x000a0;%) and did not differ between groups.</p></sec><sec><title>Conclusions</title><p>The use of very low <italic>V</italic><sub>T</sub> combined with extracorporeal CO<sub>2</sub> removal has the potential to further reduce VILI compared with a &#x02018;normal&#x02019; lung protective management. Whether this strategy will improve survival in ARDS patients remains to be determined (Clinical trials NCT 00538928).</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00134-012-2787-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Lung protective ventilation</kwd><kwd>Pumpless extracorporeal lung support</kwd><kwd>Carbon dioxide removal</kwd><kwd>Acute respiratory distress syndrome</kwd><kwd>Ultraprotective ventilation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg and ESICM 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Acute respiratory distress syndrome (ARDS) is characterized by damage to the lung parenchyma, caused by either indirect or direct insults, including ventilation itself [<xref ref-type="bibr" rid="CR1">1</xref>]. Tidal hyperinflation and cyclic alveolar recruitment/derecruitment during mechanical ventilation can lead to an entity called ventilator induced lung injury (VILI) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. A multi-centered clinical trial demonstrated that a lung protective strategy with tidal volumes (<italic>V</italic><sub>T</sub>&#x02019;s) of 6&#x000a0;ml/kg predicted body weight (PBW), and plateau pressures &#x02264;30&#x000a0;cmH<sub>2</sub>O decreased mortality by a relative 22&#x000a0;% compared to control [<xref ref-type="bibr" rid="CR4">4</xref>]. A post hoc analysis of this study [<xref ref-type="bibr" rid="CR5">5</xref>] found that the lower the plateau pressure (<italic>P</italic><sub>plat</sub>), the better the patient&#x02019;s chances of survival, even for <italic>P</italic><sub>plat</sub> substantially &#x0003c;30&#x000a0;cmH<sub>2</sub>O, and these data suggested that even lower tidal volumes might further improve survival. Grasso and colleagues [<xref ref-type="bibr" rid="CR6">6</xref>] demonstrated that many ARDS patients ventilated using the ARDSNet strategy with table-based PEEP have a stress index indicating alveolar hyperinflation.</p><p>These data would suggest the use of even lower tidal volumes, but in severe ARDS the implementation of such a strategy may be limited by a therapeutic dilemma due to the increased likelihood of more severe hypercapnia and acidosis. The impact of hypercapnia on lung injury or on systemic effects including remote organ damage (myocardial insufficiency, renal failure, and hepatic/intestinal ischemia) is somewhat controversial [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], delaying or preventing the implementation of adequate lung-protective strategies [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>In the last few years, extracorporeal, pumpless arterio-venous approaches to CO<sub>2</sub> removal using an artificial membrane lung have been developed and tested for clinical use retrospectively in 90 patients [<xref ref-type="bibr" rid="CR10">10</xref>] demonstrating marked carbon dioxide removal and moderate oxygenation improvement. Additionally, in a prospective cohort study Terragni and coworkers [<xref ref-type="bibr" rid="CR11">11</xref>] used a CO<sub>2</sub> removal device to reduce tidal volume lower than 6&#x000a0;ml/kg and observed an improvement of morphological markers of lung protection. However, their study was not a randomized clinical trial and there was no concurrent control group. We set out to investigate the effects of combining a very low <italic>V</italic><sub>T</sub> (3&#x000a0;ml/kg PBW) with arterio-venous extracorporeal CO<sub>2</sub>-elimination (avECCO<sub>2</sub>-R) in patients suffering from established ARDS.</p><p>We hypothesized mechanical ventilation using lower tidal volumes (3&#x000a0;ml/kg) assisted by avECCO<sub>2</sub>-R would enhance lung protection and hence increase 28-day and 60-day ventilator-free days, compared with mechanical ventilation using conventional tidal volumes (6&#x000a0;ml/kg).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>The study was approved by the ethics committee of the Regensburg University Hospital (reference 07/012), and the ethics committees of all involved study centers. Before enrolment, written informed consent was obtained from the legal proxy of each patient. Patients were enrolled from September 2007 through December 2010 at eight intensive care units (ICU) in Germany and two ICU&#x02019;s in Austria.</p><p>Entry criteria were: (1) presence of ARDS according to the American-European Consensus Conference [<xref ref-type="bibr" rid="CR12">12</xref>] defined by bilateral infiltrates on chest X-ray, and a PaO<sub>2</sub>/FIO<sub>2</sub> &#x0003c;200 present for at least 2&#x000a0;h. At the time of screening patients could not have any evidence of left ventricular failure; (2) age &#x02265;18&#x000a0;years; (3) history of mechanical ventilation &#x0003c;7&#x000a0;days); (4) plateau pressure &#x0003e;25&#x000a0;cmH<sub>2</sub>O at defined ventilator settings (PEEP/FIO<sub>2</sub>-table&#x000a0;+&#x000a0;<italic>V</italic><sub>T</sub>&#x000a0;=&#x000a0;6&#x000a0;ml/kg); (5) absence of severe hemodynamic instability with high demand for vasopressors (mean arterial pressure &#x02265;70&#x000a0;mmHg with continuous norepinephrine infusion &#x02264;0.4&#x000a0;&#x003bc;g/kg/min). Exclusion criteria were: decompensated heart insufficiency, acute coronary syndrome, severe chronic obstructive pulmonary disease, advanced malignancy with life expectancy &#x0003c;6&#x000a0;months, chronic dialysis treatment, lung transplant patients, proven heparin-induced thrombocytopenia (HIT), morbid obesity (body mass index &#x0003e;40&#x000a0;kg/m<sup>2</sup>), cirrhosis of the liver Child Class &#x02265;B (Child&#x02013;Pugh scores &#x02265;7), or acute fulminant hepatic failure, severe peripheral arterial occlusive disease, absence of limb doppler pulse, and acute brain injury (Glasgow Coma Scale &#x02264;9).</p><p>To identify patients presenting with established ARDS and to help further rule out patients with acute cardiogenic pulmonary edema, the screening was followed by a stabilization period for 24&#x000a0;h, characterized by lung protective mechanical ventilation with high PEEP (&#x02265;12&#x000a0;cmH<sub>2</sub>O), the use of supportive measures, and hemodynamic evaluation (echocardiography). Patients who had ARDS criteria (PaO<sub>2</sub>/FIO<sub>2</sub> &#x0003c;200) after 24&#x000a0;h despite optimal supportive treatment were identified as those with established ARDS [<xref ref-type="bibr" rid="CR13">13</xref>], and were randomized through phone hot line by a random number table generated by the involved statistician with respect to the stratum pulmonary/non-pulmonary ARDS (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The principal investigator (TB) performed visits aimed at information and supervision of the study protocol in the participating centers. An independent Data Safety Monitoring Board monitored the study.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Screening, randomization and follow-up according to study protocol. <italic>V</italic><sub><italic>T</italic></sub> tidal volume, <italic>CVP</italic> central venous pressure, <italic>MAP</italic> mean arterial pressure, <italic>vvECMO</italic> veno-venous ECMO</p></caption><graphic xlink:href="134_2012_2787_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Treatment of the study group</title><p>The intensive care management in both groups followed the &#x02018;best clinical evidence&#x02019; recommended by the European Society of Intensive Care Medicine [<xref ref-type="bibr" rid="CR14">14</xref>]. The daily monitoring included the assessment of awakeness/sedation (Richmond Agitation Sedation Scale [RASS]) and the daily evaluation of the Sequential Organ Failure Assessment (SOFA) and the Simplified Acute Physiology Score (SAPS-II).</p><p>After randomization to the treatment group, percutaneous cannulation and initiation of pumpless extracorporeal lung assist (iLA AV, Novalung, Heilbronn, Germany) was performed. Unlike &#x0201c;classic&#x0201d; pump-driven extracorporeal carbon dioxide removal, iLA does not require a blood pump, because the extremely low resistance of this circuit allows flows of about 1&#x02013;2&#x000a0;l/min with normal arterial pressures (for more detailed description: [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]). Evaluation, cannulation and clinical monitoring for avECCO<sub>2</sub>-R can be found in electronic supplementary material (ESM).</p><p>After initiation of avECCO<sub>2</sub>-R, adaptation of the ventilation strategy according to study protocol was performed as follows: a rapid titration down to <italic>V</italic><sub>T</sub> 3&#x000a0;ml/kg/PBW, PEEP following ARDSNet &#x0201c;high-PEEP/FIO<sub>2</sub>&#x0201d; table [<xref ref-type="bibr" rid="CR16">16</xref>], respiratory rate 10&#x02013;25/min with an inspiratory/expiratory ratio of 1:1. Termination of the avECCO<sub>2</sub>-R therapy and decannulation was performed according to a defined algorithm (see ESM).</p></sec><sec id="Sec5"><title>Treatment of the control group</title><p>The ventilatory management followed the algorithm of the study group except for the use of a <italic>V</italic><sub>T</sub>&#x000a0;=&#x000a0;6&#x000a0;ml/kg/PBW. The target blood gases for both groups were: PaO<sub>2</sub> &#x02265;60&#x000a0;mmHg and arterial pH &#x02265;7.2. The use of buffering (tris-(hydroxymethyl) aminomethane [TRIS]) was permitted if the patient had hypercapnia and respiratory acidosis (pH &#x0003c;7.2).</p></sec><sec id="Sec6"><title>Weaning and extubation procedures</title><p>In both groups daily screening was performed as a precondition for carrying out a spontaneous breathing trial (SBT): ability to breathe spontaneously (FIO<sub>2</sub> &#x02264;0.4, SaO<sub>2</sub> &#x02265;90&#x000a0;%, PEEP &#x02264;8&#x000a0;cmH<sub>2</sub>O, hemodynamic stability, RASS score &#x02265;&#x02212;1, body temperature &#x0003c;38.5&#x000b0;).</p><p>SBT was carried out over 1&#x000a0;h with augmented spontaneous breathing (ASB) 5&#x000a0;cmH<sub>2</sub>O with an active humidifier or, 10&#x000a0;cmH<sub>2</sub>O with HME filter (PEEP &#x02264;8&#x000a0;cmH<sub>2</sub>O, flow trigger &#x0003c;3&#x000a0;l/min). Patients were extubated when no deterioration was observed over a 1&#x000a0;h period.</p></sec><sec id="Sec7"><title>Data collection</title><p>At the time of screening (24&#x000a0;h prior to randomization) physiologic data were recorded and relevant laboratory, radiographic and clinical findings were collected. Throughout the complete study period, data on ventilator settings, laboratory, physiologic, radiographic and interventional data were recorded. Relevant data of the ventilation management (<italic>V</italic><sub>T</sub>, PEEP, <italic>P</italic><sub>plat</sub>, minute ventilation, proportion of spontaneous ventilation on minute ventilation, arterial oxygen saturation) as well as results of the blood gas analyses (PaO<sub>2</sub>, PaCO<sub>2</sub>, pH) were recorded three times daily (8 a.m., 2 p.m., 10 p.m.) and the mean values of repeated measures were used for further analysis. SOFA score, SAPS-II and RASS scores were calculated daily (8 a.m.).</p><p>In addition, in a subgroup of study patients of the Regensburg University Hospital, depending on &#x02018;in-the-daytime&#x02019;-availability of requested lab values, the levels of proinflammatory cytokines (tumour necrosis factor [TNF], interleukin 6 [IL-6] and interleukin 8 [IL-8]) were assessed from serum probes of avECCO<sub>2</sub>-R-patients (<italic>n</italic>&#x000a0;=&#x000a0;20) and control patients (<italic>n</italic>&#x000a0;=&#x000a0;15) at various time points during the study, since the measurement of these parameters is part of the routine laboratory program in this hospital. Furthermore, in all participating centers the daily cumulative doses of vasopressors (norepinephrine, adrenaline, dobutamine), sedative and analgesic agents (sufentanil, propofol, midazolam) and net fluid balances were calculated in each patient and recorded.</p></sec><sec id="Sec8"><title>Primary outcome</title><p>The primary outcome parameter was the proportion of days without assisted ventilation in a 28-day period (&#x0201c;ventilator-free&#x0201d; days within 28&#x000a0;days [28-VFD]) and in a 60&#x000a0;days period (&#x0201c;ventilator-free&#x0201d; days within 60&#x000a0;days [60-VFD]) [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec9"><title>Secondary outcomes</title><p>Secondary outcomes were: inspiratory plateau pressure levels (<italic>P</italic><sub>plat</sub>), the proportion of spontaneous breathing as a percentage of the minute ventilation (automatically calculated by the ventilator&#x02019;s software), the RASS score, hemodynamic changes, the incidence of complications or adverse reactions, the frequency and duration of other adjunctive therapeutic measures, transfusion requirements [packed red blood cell transfusions (units), fresh frozen plasma units, platelet transfusion], the daily cumulative doses of analgesic and sedative agents, cumulative catecholamine requirements/24&#x000a0;h throughout the study period, frequency and duration of renal replacement therapy, the number of failing organs, the &#x0201c;organ-failure-free days&#x0201d; within 28&#x000a0;days after randomisation, and &#x0201c;in-hospital&#x0201d; mortality.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p>Assuming an increase in 28-VFD from 6.0&#x000a0;&#x000b1;&#x000a0;10 (control group) to 11.0&#x000a0;&#x000b1;&#x000a0;8 (study group [<xref ref-type="bibr" rid="CR13">13</xref>]), we estimated that 53 patients would be needed per group for a power of 0.8 and an alpha of 0.05 (calculation by Charit&#x000e8; Centrum f&#x000fc;r Therapieforschung, Berlin, Germany). We assumed a &#x0201c;drop-out-rate&#x0201d; of 10&#x000a0;% and we calculated that 120 patients would need to be enrolled. However, after an interim analysis with 56 patients by the Data Safety Monitoring Board, it was decided to limit the study period to 3&#x000a0;years, since a statistical significant difference was not expected in a longer study period.</p><p>We used a Student&#x02019;s <italic>t</italic>-test, the Wilcoxon test, the chi-square test or Fisher&#x02019;s exact test to assess differences between the groups, as appropriate. A Kaplan&#x02013;Meier curve was calculated and plotted to assess the days until successful weaning from the ventilator. Furthermore, a nonparametric analysis of longitudinal data in factorial experiments was performed. Changes in interesting clinical outcomes with respect to time were analyzed using multivariate nonparametric analysis of longitudinal data in a two-factorial design (1st [independent] factor: groups, 2nd [dependent] factor: repetitions in time). Therefore, all the time points were simultaneously compared on the corresponding response curves (analysis according to Brunner [Brunner-analysis <xref ref-type="bibr" rid="CR18">18</xref>]). Additionally, a post hoc analysis was performed in patients with greater hypoxemia (PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;150) regarding primary outcome parameters. The reported <italic>P</italic> values are two-sided and significance was set at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><p>Between September 2007 and December 2010, 40 patients were randomized to avECCO<sub>2</sub>-R and 39 patients to control. Baseline data are given in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Patients did not differ with respect to age and body mass index, but in the avECCO<sub>2</sub>-R-group there were more patients with secondary ARDS. Ventilatory and gas exchange data are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">avECCO<sub>2</sub>-R (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th align="left">Control (<italic>n</italic>&#x000a0;=&#x000a0;39)</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">49.8&#x000a0;&#x000b1;&#x000a0;12</td><td align="left">48.7&#x000a0;&#x000b1;&#x000a0;17</td></tr><tr><td align="left">Gender (male/female)</td><td align="left">38/2</td><td align="left">30/9</td></tr><tr><td align="left">Lung Injury Score (Murray)</td><td align="left">2.8&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">2.7&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">28.6&#x000a0;&#x000b1;&#x000a0;5</td><td align="left">28.8&#x000a0;&#x000b1;&#x000a0;5</td></tr><tr><td align="left" colspan="3">Source of ARDS</td></tr><tr><td align="left">&#x000a0;Pulmonary/non-pulmonary ARDS</td><td align="left">31/9</td><td align="left">37/2</td></tr><tr><td align="left" colspan="3"><italic>Non</italic>-<italic>pulmonary</italic></td></tr><tr><td align="left">SIRS/Sepsis</td><td align="left">5</td><td align="left">1</td></tr><tr><td align="left">Massive transfusion</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">Trauma</td><td align="left">3</td><td align="left">1</td></tr><tr><td align="left" colspan="3"><italic>Pulmonary</italic></td></tr><tr><td align="left">Pneumonia</td><td align="left">24 (58&#x000a0;% bacterial)</td><td align="left">21 (62&#x000a0;% bacterial)</td></tr><tr><td align="left">Aspiration</td><td align="left">1</td><td align="left">6</td></tr><tr><td align="left">Lung contusion</td><td align="left">6</td><td align="left">9</td></tr><tr><td align="left">Inhalation</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left" colspan="3">Comorbidities</td></tr><tr><td align="left">&#x000a0;Diabetes mellitus</td><td align="left">2</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;COPD</td><td align="left">5</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;Arterial hypertension</td><td align="left">10</td><td align="left">7</td></tr><tr><td align="left">&#x000a0;Coronary artery disease</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Chronic renal impairment</td><td align="left">2</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Other</td><td align="left">19</td><td align="left">15</td></tr><tr><td align="left">&#x000a0;&#x000a0;Atrial fibrillation</td><td align="left">3</td><td align="left">2</td></tr><tr><td align="left">&#x000a0;&#x000a0;Alcohol use disorder</td><td align="left">2</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;&#x000a0;Obesity</td><td align="left">2</td><td align="left">3</td></tr></tbody></table><table-wrap-foot><p>The data are presented as mean&#x000a0;&#x000b1;&#x000a0;standard deviation or absolute numbers</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Ventilation parameters and gas exchange after 24-h stabilization period at randomization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">avECCO<sub>2</sub>-R (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th align="left">Control (<italic>n</italic>&#x000a0;=&#x000a0;39)</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left">PaO<sub>2</sub>/FIO<sub>2</sub></td><td char="&#x000b1;" align="char">152&#x000a0;&#x000b1;&#x000a0;37</td><td char="&#x000b1;" align="char">168&#x000a0;&#x000b1;&#x000a0;37</td><td char="." align="char">0.044</td></tr><tr><td align="left">PaCO<sub>2</sub> (mmHg)</td><td char="&#x000b1;" align="char">57.3&#x000a0;&#x000b1;&#x000a0;12</td><td char="&#x000b1;" align="char">54.3&#x000a0;&#x000b1;&#x000a0;9</td><td char="." align="char">0.352</td></tr><tr><td align="left">Arterial pH</td><td char="&#x000b1;" align="char">7.34&#x000a0;&#x000b1;&#x000a0;0.07</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.07</td><td char="." align="char">0.317</td></tr><tr><td align="left"><italic>V</italic><sub>T</sub> (ml/kg, PBW)</td><td char="&#x000b1;" align="char">5.9&#x000a0;&#x000b1;&#x000a0;1.2</td><td char="&#x000b1;" align="char">6.0&#x000a0;&#x000b1;&#x000a0;0.6</td><td char="." align="char">0.495</td></tr><tr><td align="left">Minute ventilation (l/min)</td><td char="&#x000b1;" align="char">9.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td char="&#x000b1;" align="char">9.8&#x000a0;&#x000b1;&#x000a0;2.4</td><td char="." align="char">0.745</td></tr><tr><td align="left">Frequency/min</td><td char="&#x000b1;" align="char">22.4&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">22.7&#x000a0;&#x000b1;&#x000a0;3.5</td><td char="." align="char">0.854</td></tr><tr><td align="left">PEEP (cmH<sub>2</sub>O)</td><td char="&#x000b1;" align="char">16.1&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">16.0&#x000a0;&#x000b1;&#x000a0;3</td><td char="." align="char">0.898</td></tr><tr><td align="left">Plateau pressure (cmH<sub>2</sub>O)</td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;5</td><td char="&#x000b1;" align="char">28.0&#x000a0;&#x000b1;&#x000a0;7</td><td char="." align="char">0.384</td></tr><tr><td align="left">Delta (PEEP-Plateau) (cmH<sub>2</sub>O)</td><td char="&#x000b1;" align="char">12.9&#x000a0;&#x000b1;&#x000a0;4</td><td char="&#x000b1;" align="char">12.4&#x000a0;&#x000b1;&#x000a0;4</td><td char="." align="char">0.475</td></tr><tr><td align="left">FIO<sub>2</sub></td><td char="&#x000b1;" align="char">0.62&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">0.53&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.028</td></tr></tbody></table><table-wrap-foot><p>The data are presented as mean&#x000a0;&#x000b1;&#x000a0;standard deviation</p></table-wrap-foot></table-wrap></p><p>Initially all patients were ventilated with high PEEP and low tidal volume according to the ARDSNet protocol, and had moderate hypercapnia. At randomization there were no significant differences regarding mean arterial pressure, heart rate or demand vasopressor uses (data not shown). However, there was a significantly lower PaO<sub>2</sub>/FIO<sub>2</sub>-ratio in the intervention arm. The mean duration of iLA-treatment was 7.4&#x000a0;&#x000b1;&#x000a0;4&#x000a0;days with a mean blood flow of 1.3&#x000a0;&#x000b1;&#x000a0;0.2&#x000a0;l/min throughout the treatment period.</p><sec id="Sec12"><title>Primary outcome results</title><p>We found no statistical differences in VFD-28 or VFD-60 between groups, (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), but a post hoc analysis demonstrated that surviving patients with greater hypoxemia (PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;150 at randomization) treated with avECCO<sub>2</sub>-R had a significantly shorter period of ventilation (VFD-60&#x000a0;=&#x000a0;40.9&#x000a0;&#x000b1;&#x000a0;12.8) compared to control (28.2&#x000a0;&#x000b1;&#x000a0;16.4, <italic>p</italic>&#x000a0;=&#x000a0;0.033) Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Non-pulmonary organ failure free days within 60&#x000a0;days, intensive care and hospital days were not statistically different between groups.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Outcome parameters of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">All patients</th><th align="left" colspan="3">Subgroup: PaO<sub>2</sub>/FIO<sub>2</sub> &#x0003c;150</th></tr><tr><th align="left">avECCO<sub>2</sub>-R</th><th align="left">Control</th><th align="left"><italic>p</italic></th><th align="left">avECCO<sub>2</sub>-R</th><th align="left">Control</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left">Ventilator-free-days-28</td><td align="left">10.0&#x000a0;&#x000b1;&#x000a0;8</td><td align="left">9.3&#x000a0;&#x000b1;&#x000a0;9</td><td char="." align="char">0.779</td><td align="left">11.3&#x000a0;&#x000b1;&#x000a0;7.5</td><td align="left">5.0&#x000a0;&#x000b1;&#x000a0;6.3</td><td char="." align="char">0.033</td></tr><tr><td align="left">Ventilator-free-days-60</td><td align="left">33.2&#x000a0;&#x000b1;&#x000a0;20</td><td align="left">29.2&#x000a0;&#x000b1;&#x000a0;21</td><td char="." align="char">0.469</td><td align="left">40.9&#x000a0;&#x000b1;&#x000a0;12.8</td><td align="left">28.2&#x000a0;&#x000b1;&#x000a0;16.4</td><td char="." align="char">0.033</td></tr><tr><td align="left">Non-pulmonary organ failure free days-60</td><td align="left">21.0&#x000a0;&#x000b1;&#x000a0;14</td><td align="left">23.9&#x000a0;&#x000b1;&#x000a0;15</td><td char="." align="char">0.447</td><td align="left">24.1&#x000a0;&#x000b1;&#x000a0;7.5</td><td align="left">29.0&#x000a0;&#x000b1;&#x000a0;17.7</td><td char="." align="char">0.428</td></tr><tr><td align="left">Lung injury score on day 10</td><td align="left">2.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">2.1&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="." align="char">0.854</td><td align="left">2.3&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">2.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="." align="char">0.601</td></tr><tr><td align="left">Length of stay in hospital (days)</td><td align="left">46.7&#x000a0;&#x000b1;&#x000a0;33</td><td align="left">35.1&#x000a0;&#x000b1;&#x000a0;17</td><td char="." align="char">0.113</td><td align="left">42.0&#x000a0;&#x000b1;&#x000a0;16.6</td><td align="left">40.3&#x000a0;&#x000b1;&#x000a0;15.7</td><td char="." align="char">0.815</td></tr><tr><td align="left">Length of stay in ICU (days)</td><td align="left">31.3&#x000a0;&#x000b1;&#x000a0;23</td><td align="left">22.9&#x000a0;&#x000b1;&#x000a0;11</td><td char="." align="char">0.144</td><td align="left">25.9&#x000a0;&#x000b1;&#x000a0;13.1</td><td align="left">31.0&#x000a0;&#x000b1;&#x000a0;12.7</td><td char="." align="char">0.258</td></tr><tr><td align="left">In-hospital mortality</td><td align="left">7/40 (17.5&#x000a0;%)</td><td align="left">6/39 (15.4&#x000a0;%)</td><td char="." align="char">1.000</td><td align="left">1/21 (4.8&#x000a0;%)</td><td align="left">1/10 (10&#x000a0;%)</td><td char="." align="char">0.563</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Post-hoc analysis: probability of successful weaning in patients presenting with PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;150 versus &#x0003e;150 (only surviving patients)</p></caption><graphic xlink:href="134_2012_2787_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Secondary outcome results</title><p>After insertion of pumpless extracorporeal lung assist, a <italic>V</italic><sub>T</sub> of 3&#x000a0;ml/kg PBW was achieved in most patients which increased moderately (as spontaneous breathing increased) to day 6 after randomization (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), while in control patients <italic>V</italic><sub>T</sub> increased from 6&#x000a0;ml to 8&#x000a0;ml/kg/PBW (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 between groups). Minute ventilation was significantly decreased, and the difference between plateau pressure and PEEP (<italic>P</italic><sub>plat</sub>&#x000a0;&#x02212;&#x000a0;PEEP) was significantly reduced in study patients compared to control.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Mean tidal volumes (ml per kg predicted body weight), minute ventilation and difference of plateau pressure and PEEP (<italic>P</italic><sub>plat</sub>&#x000a0;&#x02212;&#x000a0;PEEP), in the treatment and control groups during the study period</p></caption><graphic xlink:href="134_2012_2787_Fig3_HTML" id="MO3"/></fig></p><p>The fractional amount of augmented spontaneous breathing as a percent of total minute ventilation was significantly increased from day 3 in avECCO<sub>2</sub>-R compared to control (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Percent of spontaneous ventilation on minute ventilation and oxygenation (PaO<sub>2</sub>/FIO<sub>2</sub>) in the treatment and control groups during the study period</p></caption><graphic xlink:href="134_2012_2787_Fig4_HTML" id="MO4"/></fig></p><p>In line with previous data, extracorporeal CO<sub>2</sub> removal required higher FIO<sub>2</sub> which is thought to be due to the lower partial pressure of alveolar oxygen (PAO<sub>2</sub>) secondary to a decreased lung respiratory quotient [<xref ref-type="bibr" rid="CR19">19</xref>], and due to a reduction in functional residual capacity with a <italic>V</italic><sub>T</sub> of 3&#x000a0;ml/kg compared to 6&#x000a0;ml/kg [<xref ref-type="bibr" rid="CR20">20</xref>]. PaCO<sub>2</sub>-values, arterial pH, and mean respiratory rates/min were similar between groups, but mean PEEP levels tended to be elevated in the study group. During the study period, patients with avECCO<sub>2</sub>-R had a modest reduction in MAP without increased demand for continuous norepinephrine infusion.</p><p>The cumulative amount of opioid (sufentanil) and benzodiazepine infusion (midazolam) was significantly lower in the study group, but mean RASS-scores were not different between groups during the study period (Fig.&#x000a0;5, ESM).</p><p>The number of units of red blood cells transfused was significantly higher in the avECCO<sub>2</sub>-R -group in the period between randomization and day 10 (3.7&#x000a0;&#x000b1;&#x000a0;2.4 units RBC) compared with control (1.5&#x000a0;&#x000b1;&#x000a0;1.3, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). The incidence of avECCO<sub>2</sub>-R -related adverse events was low (3 patients&#x000a0;=&#x000a0;7.5&#x000a0;%): in one patient, transient ischemia of the lower limb was observed, while two patients developed a &#x02018;false&#x02019; aneurysm as a result of arterial cannulation. The overall hospital mortality was low (16.5&#x000a0;%) and we found no significant difference between avECCO<sub>2</sub>-R-group (17.5&#x000a0;%) and control (15.4&#x000a0;%).</p></sec><sec id="Sec14"><title>Results of the cytokine assessments</title><p>TNF-&#x003b1;, IL-6, and IL-8 levels are presented in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. Serum TNF-&#x003b1; levels remained unchanged during the early study period in both groups, while IL-6 levels decreased significantly in the avECCO<sub>2</sub>-R-group, but not in the control group within 24&#x000a0;h after study initiation. IL-8 levels increased in the first few study days in the control group, but not in study patients.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>The serum level of tumor necrosis factor (TNF), interleukin 6 (IL-6), and interleukin 8 (IL-8) in treatment and control patients (median values and 25/75 percentiles)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">TNF (pg/ml)</th><th align="left">Before begin of the study</th><th align="left">24&#x000a0;h</th><th align="left">48&#x000a0;h</th><th align="left">72&#x000a0;h</th></tr></thead><tbody><tr><td align="left">avECCO<sub>2</sub>-R (<italic>n</italic>&#x000a0;=&#x000a0;20)</td><td char="(" align="char">19.8 (13.8&#x02013;23)</td><td char="(" align="char">20 (13.2&#x02013;23.6)</td><td char="(" align="char">15.3 (13.7&#x02013;21.4)</td><td char="(" align="char">22.5 (12.8&#x02013;33.2)</td></tr><tr><td align="left">Control (<italic>n</italic>&#x000a0;=&#x000a0;15)</td><td char="(" align="char">20.5 (14.2&#x02013;26.8)</td><td char="(" align="char">21 (13.9&#x02013;48.6)</td><td char="(" align="char">15.9 (13.6&#x02013;28)</td><td char="(" align="char">15.2 (12.7&#x02013;25)</td></tr><tr><td align="left" colspan="5">IL-6 (pg/ml)</td></tr><tr><td align="left">&#x000a0;avECCO<sub>2</sub>-R (<italic>n</italic>&#x000a0;=&#x000a0;20)</td><td char="(" align="char">163 (86&#x02013;419)</td><td char="(" align="char">85 (50&#x02013;193)<sup><bold>$</bold></sup></td><td char="(" align="char">53 (20&#x02013;109)<sup><bold>$$</bold></sup></td><td char="(" align="char">60 (35&#x02013;155)<sup><bold>$</bold></sup></td></tr><tr><td align="left">&#x000a0;Control (<italic>n</italic>&#x000a0;=&#x000a0;15)</td><td char="(" align="char">97 (84&#x02013;214)</td><td char="(" align="char">111 (52&#x02013;171)</td><td char="(" align="char">102 (58&#x02013;166)</td><td char="(" align="char">64 (18&#x02013;90)</td></tr><tr><td align="left" colspan="5">IL-8 (ng/l)</td></tr><tr><td align="left">&#x000a0;avECCO<sub>2</sub>-R (<italic>n</italic>&#x000a0;=&#x000a0;20)</td><td char="(" align="char">72 (23&#x02013;98)</td><td char="(" align="char">65 (30&#x02013;100)</td><td char="(" align="char">71 (28&#x02013;94)</td><td char="(" align="char">81 (43&#x02013;120)</td></tr><tr><td align="left">&#x000a0;Control (<italic>n</italic>&#x000a0;=&#x000a0;15)</td><td char="(" align="char">34 (23&#x02013;49)</td><td char="(" align="char">36 (24&#x02013;126)</td><td char="(" align="char">45 (29&#x02013;529)</td><td char="(" align="char">25 (17&#x02013;191)</td></tr></tbody></table><table-wrap-foot><p><sup><bold>$</bold></sup><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 in comparison with before</p><p><sup><bold>$$</bold></sup><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01 in comparison with before</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>Lung protective ventilation using <italic>V</italic><sub>T</sub>&#x02019;s of 6&#x000a0;ml/kg/PBW and limiting <italic>P</italic><sub>plat</sub> to 30&#x000a0;cmH<sub>2</sub>O improves outcomes in patients with acute lung injury [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the concept that this approach may not be sufficiently lung protective in all patients has been suggested by a post hoc analysis of the ARDSNet data [<xref ref-type="bibr" rid="CR5">5</xref>], by animal investigations [<xref ref-type="bibr" rid="CR21">21</xref>], human physiological studies [<xref ref-type="bibr" rid="CR3">3</xref>], and by a clinical study [<xref ref-type="bibr" rid="CR11">11</xref>]. We extended these findings in patients with severe established ARDS by performing a prospective randomized trial using a strategy of very low tidal volume ventilation (3&#x000a0;ml/kg) and an extracorporeal lung assist system providing CO<sub>2</sub>-elimination.</p><p>The main findings of our study are: (1) Ventilation with &#x02248;3&#x000a0;ml/kg PBW combined with avECCO<sub>2</sub>-R was safe and feasible, and did not result in physiologically relevant hypercapnia/acidosis. (2) The use of extracorporeal CO<sub>2</sub>-elimination was associated with a significant reduction in analgesic and sedative use, and resulted in an increased ratio of spontaneous breathing compared to control. (3) The serum levels of the pro-inflammatory cytokine IL-6 were significantly reduced in the early study period in patients treated with very low <italic>V</italic><sub>T</sub> compared to control patients, and (4) Mechanical ventilation using lower tidal volumes (3&#x000a0;ml/kg) assisted by extracorporeal CO<sub>2</sub>-removal was not associated with a significant reduction of the period of mechanical ventilation within 28 or 60&#x000a0;days or the intensive care and hospital stay, but a post hoc analysis demonstrated that ARDS patients who were more hypoxemic (PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;150 at randomization) at baseline and who were treated with the low <italic>V</italic><sub>T</sub> strategy had a significantly shorter ventilation period.</p><p>The strength of this study is the evaluation of patients with &#x02018;established&#x02019; ARDS: We only accepted patients for randomization who passed a &#x02018;stabilization period&#x02019; (24-h ventilation period with high PEEP) and other measures of optimization and who continued to have persistent impairment of oxygenation (PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264;200). In a recent analysis [<xref ref-type="bibr" rid="CR13">13</xref>] this patient group was identified as having a high mortality compared to patients with PaO<sub>2</sub>/FIO<sub>2</sub> &#x0003e;200. However, our study has limitations. Due to a restriction of the enrolment period to 3&#x000a0;years and a &#x02018;strict&#x02019; recruitment protocol we did not reach the pre-specified sample size. Another limitation is the fact that we only enrolled patients with stable hemodynamics, since severe cardiovascular instability was an exclusion criterion for the pumpless circuit. This exclusion criterion might explain the very low mortality rate in the overall study population.</p><p>Tidal hyperinflation [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], and cyclic recruitment/derecruitment [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] are important mechanisms leading to ventilator-induced lung injury in patients with ARDS, but sufficient clinical data are lacking indicating that a reduction of these phenomena is beneficial. The inhomogeneously injured lung leads to heterogeneous distribution of airway pressure and <italic>V</italic><sub>T</sub>, resulting in partial hyperinflation, cyclic opening and closing of moderate injured lung regions, and no ventilation in atelectatic regions, making it difficult to chose a single <italic>V</italic><sub>T</sub> that completely limits &#x02018;global&#x02019; stress/strain injury [<xref ref-type="bibr" rid="CR25">25</xref>]. Since it is not possible to adopt ventilation to the protective &#x02018;demands&#x02019; of different lung regions, we hypothesized that even a small <italic>V</italic><sub>T</sub> of 6&#x000a0;ml/kg might aggravate VILI, and therefore we carried out the first reported randomized controlled study using a very low tidal volume lung strategy.</p><p>Our data demonstrate the integration of augmented spontaneous breathing in the ventilation management of severe ARDS patients [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] without a consequent increase in tidal volume or in the demand for sedative agents. We hypothesize that avECCO<sub>2</sub>-R might allow an easy &#x02018;switch&#x02019; from controlled low <italic>V</italic><sub>T</sub>-ventilation to augmented spontaneous breathing with minimal patient-ventilator asynchrony. Although we did not formally assess ineffective breathing or other signs of asynchrony, we demonstrated that the respiratory rate was not different between the groups, whereas the demand for sedation was significantly lower in the avECCO<sub>2</sub>-R group. A reduction of the hypercapnia likely resulted in decreased respiratory drive as shown by Karagiannidis and coworkers [<xref ref-type="bibr" rid="CR28">28</xref>] using neurally adjusted ventilatory assist (NAVA).</p><p>In the present study, avECCO<sub>2</sub>-R required higher fractional inspiratory oxygen concentration to maintain adequate oxygenation, while both patient groups were treated with the same high PEEP management. There are two possible mechanisms to explain this finding. The first is a decrease in alveolar ventilation due to the removal of CO<sub>2</sub> by the extracorporeal circuit [<xref ref-type="bibr" rid="CR19">19</xref>], and the second mechanism relates to potential de-recruitment of the lung as demonstrated by Dembinski et al. [<xref ref-type="bibr" rid="CR29">29</xref>] in a lung lavage animal model (<italic>V</italic><sub>T</sub> 3&#x000a0;ml/kg and avECCO<sub>2</sub>-R). However, in this study the authors used a relatively low PEEP level (5&#x000a0;cmH<sub>2</sub>O), where we used a &#x02018;high PEEP strategy&#x02019;. Such a finding is of clinical relevance when considering extracorporeal CO<sub>2</sub>-elimination as an adjunct measure for lung protective ventilation [<xref ref-type="bibr" rid="CR30">30</xref>] with very low <italic>V</italic><sub>T</sub> [<xref ref-type="bibr" rid="CR31">31</xref>]. A &#x02018;safe border&#x02019; of <italic>V</italic><sub>T</sub> to derecruitment is not known.</p><p>On the other hand use of very small <italic>V</italic><sub>T</sub>&#x02019;s might reduce VILI. Using an experimental model, Frank et al. [<xref ref-type="bibr" rid="CR21">21</xref>] demonstrated that a reduction in <italic>V</italic><sub>T</sub> from 6 to 3&#x000a0;ml/kg led to a further reduction of epithelial and endothelial injury (extravascular lung water, alveolar epithelial type I cell antigen [RT 140]) in acid-injured rat lungs. In line with these experimental findings we found that ventilation with very low <italic>V</italic><sub>T</sub> reduced serum levels of the proinflammatory cytokine IL-6 compared with &#x02018;normal&#x02019; protective <italic>V</italic><sub>T</sub>.</p><p>In recent years, techniques of extracorporeal lung support have become easier to use, with smaller devices and greater efficacy. There is evidence that this has led to a reduction in the rate of severe complications [<xref ref-type="bibr" rid="CR32">32</xref>]. In the present study only moderate complications attributable to avECCO<sub>2</sub>-R occurred in three patients (7.5&#x000a0;%), and none led to permanent impairment. This complication rate is down from 24 and 12&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], likely related to the use of a screening algorithm, careful evaluation, new material and a modified insertion technique [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>In summary, we demonstrate that the use of very low tidal volume (&#x02248;3&#x000a0;ml/kg PBW) combined with extracorporeal elimination of carbon dioxide is feasible without major side effects and might be beneficial in the treatment of patients with severe ARDS. The integration of augmented spontaneous breathing might be easier and more comfortable with extracorporeal CO<sub>2</sub>-removal, and a reduced demand for sedative and analgesic medication could be advantageous. Future studies are required to determine whether &#x02018;ultraprotective&#x02019; ventilation will improve survival in patients suffering from severe ARDS.</p></sec><sec sec-type="supplementary-material" id="AppESM1"><title>Electronic supplementary material</title><sec id="SecESM1"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="134_2012_2787_MOESM1_ESM.doc" mimetype="application" mime-subtype="msword"><caption><p>Supplementary material 1 (DOC 82&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><fn-group><fn><p>T. Bein and S. Weber-Carstens contributed equally to the work.</p></fn><fn><p>This article is discussed in the editorial available at doi:10.1007/s00134-012-2805-8.</p></fn></fn-group><ack><p>We are grateful to the Members of the Data Safety Monitoring Board, Konrad Falke, Berlin, Germany, and Peter Suter, Geneva, Switzerland. This study was supported by a grant from Novalung, Heilbronn, Germany.</p><sec id="d30e2073"><title>Conflicts of interest</title><p>T. Bein and A. Slutsky are consults for Novalung and received honoraria. A. Slutsky is also a consultant to Maquet Medical. The other authors declare no conflicts of interest.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>The acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1334</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421806</pub-id><pub-id pub-id-type="pmid">10793167</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terragni</surname><given-names>PP</given-names></name><name><surname>Rosboch</surname><given-names>G</given-names></name><name><surname>Tealdi</surname><given-names>A</given-names></name><name><surname>Corno</surname><given-names>E</given-names></name><name><surname>Menaldo</surname><given-names>E</given-names></name><name><surname>Davini</surname><given-names>O</given-names></name><name><surname>Gandini</surname><given-names>G</given-names></name><name><surname>Herrmann</surname><given-names>P</given-names></name><name><surname>Mascia</surname><given-names>L</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Ranieri</surname><given-names>VM</given-names></name></person-group><article-title>Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1164/rccm.200607-915OC</pub-id><pub-id pub-id-type="pmid">17038660</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>S</given-names></name><name><surname>Stripoli</surname><given-names>T</given-names></name><name><surname>Sacchi</surname><given-names>M</given-names></name><name><surname>Sacchi</surname><given-names>M</given-names></name><name><surname>Trerotoli</surname><given-names>P</given-names></name><name><surname>Staffieri</surname><given-names>F</given-names></name><name><surname>Franchini</surname><given-names>D</given-names></name><name><surname>De Monte</surname><given-names>V</given-names></name><name><surname>Valentini</surname><given-names>V</given-names></name><name><surname>Pugliese</surname><given-names>P</given-names></name><name><surname>Crovace</surname><given-names>A</given-names></name><name><surname>Driessen</surname><given-names>B</given-names></name><name><surname>Fiore</surname><given-names>T</given-names></name></person-group><article-title>Inhomogeneity of lung parenchyma during the open lung strategy: a computed tomography scan study</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>180</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1164/rccm.200901-0156OC</pub-id><pub-id pub-id-type="pmid">19542479</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Acute Respiratory Distress Syndrome Network</collab></person-group><article-title>Ventilation with lower tidal volume as compared with traditional tidal volume for acute lung injury and the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1301</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421801</pub-id><pub-id pub-id-type="pmid">10793162</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>DN</given-names></name><name><surname>Krishnan</surname><given-names>JA</given-names></name><name><surname>Hayden</surname><given-names>DL</given-names></name><name><surname>Hayden</surname><given-names>DL</given-names></name><name><surname>Brower</surname><given-names>RG</given-names></name><collab>ARDS Clinical Trials Network</collab></person-group><article-title>Tidal volume reduction in patients with acute lung injury when plateau pressures are not high</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>172</volume><fpage>1241</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1164/rccm.200501-048CP</pub-id><pub-id pub-id-type="pmid">16081547</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>S</given-names></name><name><surname>Stripoli</surname><given-names>T</given-names></name><name><surname>De Michele</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>F</given-names></name><name><surname>Moschetta</surname><given-names>M</given-names></name><name><surname>Angelelli</surname><given-names>G</given-names></name><name><surname>Munno</surname><given-names>I</given-names></name><name><surname>Ruggiero</surname><given-names>V</given-names></name><name><surname>Anaclerio</surname><given-names>R</given-names></name><name><surname>Cafarelli</surname><given-names>A</given-names></name><name><surname>Driessen</surname><given-names>B</given-names></name><name><surname>Fiore</surname><given-names>T</given-names></name></person-group><article-title>ARDSNet ventilatory protocol and alveolar hyperinflation: role of positive end-expiratory pressure</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1164/rccm.200702-193OC</pub-id><pub-id pub-id-type="pmid">17656676</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzam</surname><given-names>ZS</given-names></name><name><surname>Sharabi</surname><given-names>K</given-names></name><name><surname>Guetta</surname><given-names>J</given-names></name><name><surname>Bank</surname><given-names>EM</given-names></name><name><surname>Gruenbaum</surname><given-names>Y</given-names></name></person-group><article-title>The physiological and molecular effects of elevated CO<sub>2</sub> levels</article-title><source>Cell Cycle</source><year>2010</year><volume>15</volume><fpage>1528</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.4161/cc.9.8.11196</pub-id><pub-id pub-id-type="pmid">20372066</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltekova</surname><given-names>V</given-names></name><name><surname>Engelberts</surname><given-names>D</given-names></name><name><surname>Otulakowski</surname><given-names>G</given-names></name><name><surname>Otulakowski</surname><given-names>G</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Post</surname><given-names>M</given-names></name><name><surname>Kavanagh</surname><given-names>BP</given-names></name></person-group><article-title>Hypercapnic acidosis in ventilator-induced lung injury</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>869</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1007/s00134-010-1787-7</pub-id><pub-id pub-id-type="pmid">20213072</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Greg Carter</surname><given-names>RT</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name></person-group><article-title>Barriers to providing lung-protective ventilation to patients with acute lung injury</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><fpage>1289</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000127266.39560.96</pub-id><pub-id pub-id-type="pmid">15187508</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bein</surname><given-names>Th</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Prasser</surname><given-names>C</given-names></name><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>FX</given-names></name><name><surname>Butz</surname><given-names>B</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Taeger</surname><given-names>K</given-names></name><name><surname>Schlitt</surname><given-names>HJ</given-names></name></person-group><article-title>A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>1372</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000215111.85483.BD</pub-id><pub-id pub-id-type="pmid">16540950</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terragni</surname><given-names>PP</given-names></name><name><surname>Del Sorbo</surname><given-names>L</given-names></name><name><surname>Mascia</surname><given-names>L</given-names></name><name><surname>Urbino</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>EL</given-names></name><name><surname>Birocco</surname><given-names>A</given-names></name><name><surname>Faggiano</surname><given-names>C</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Ranieri</surname><given-names>VM</given-names></name></person-group><article-title>Tidal volume lower than 6&#x000a0;ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal</article-title><source>Anesthesiology</source><year>2009</year><volume>111</volume><fpage>826</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e3181b764d2</pub-id><pub-id pub-id-type="pmid">19741487</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Brigham</surname><given-names>KL</given-names></name><name><surname>Carlet</surname><given-names>J</given-names></name><name><surname>Falke</surname><given-names>K</given-names></name><name><surname>Hudson</surname><given-names>L</given-names></name><name><surname>Lamy</surname><given-names>M</given-names></name><name><surname>LeGall</surname><given-names>JR</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Spragg</surname><given-names>R</given-names></name></person-group><article-title>American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><fpage>818</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.149.3.7509706</pub-id><pub-id pub-id-type="pmid">7509706</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>P&#x000e9;rez-M&#x000e9;ndez</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>J</given-names></name><name><surname>Belda</surname><given-names>J</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name><name><surname>Saralegui</surname><given-names>I</given-names></name><name><surname>Su&#x000e1;rez-Sipmann</surname><given-names>F</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>J</given-names></name><name><surname>Lubillo</surname><given-names>S</given-names></name><name><surname>Kacmarek</surname><given-names>RM</given-names></name><collab>HELP Network</collab></person-group><article-title>An early PEEP/FIO<sub>2</sub> trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1164/rccm.200610-1534OC</pub-id><pub-id pub-id-type="pmid">17585106</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">ESICM Systematic Review Group (Ed.) (2011) Clinical evidence in intensive care. Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, Germany</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Bein</surname><given-names>T</given-names></name><name><surname>Arlt</surname><given-names>M</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Rupprecht</surname><given-names>L</given-names></name><name><surname>Mueller</surname><given-names>T</given-names></name><name><surname>Lubnow</surname><given-names>M</given-names></name><name><surname>Graf</surname><given-names>BM</given-names></name><name><surname>Schlitt</surname><given-names>HJ</given-names></name></person-group><article-title>Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R10</fpage><pub-id pub-id-type="doi">10.1186/cc7703</pub-id><pub-id pub-id-type="pmid">19183475</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brower</surname><given-names>RG</given-names></name><name><surname>Lanken</surname><given-names>PN</given-names></name><name><surname>Macintyre</surname><given-names>N</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Schoenfeld</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><collab>National Heart, Lung, and Blood Institute ARDS Clinical Trials Network</collab></person-group><article-title>Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032193</pub-id><pub-id pub-id-type="pmid">15269312</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><collab>ARDS Network</collab></person-group><article-title>Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>1772</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1097/00003246-200208000-00016</pub-id><pub-id pub-id-type="pmid">12163791</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Brunner</surname><given-names>E</given-names></name><name><surname>Domhof</surname><given-names>S</given-names></name><name><surname>Langer</surname><given-names>F</given-names></name></person-group><source>Nonparametric analysis of longitudinal data in factorial experiments</source><year>2002</year><publisher-loc>New York</publisher-loc><publisher-name>Wiley</publisher-name></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurigemma</surname><given-names>NM</given-names></name><name><surname>Feldman</surname><given-names>NT</given-names></name><name><surname>Gottlieb</surname><given-names>M</given-names></name><name><surname>Ingram</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Lazarus</surname><given-names>JM</given-names></name><name><surname>Lowrie</surname><given-names>EG</given-names></name></person-group><article-title>Arterial oxygenation during hemodialysis</article-title><source>N Engl J Med</source><year>1977</year><volume>297</volume><fpage>871</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1056/NEJM197710202971607</pub-id><pub-id pub-id-type="pmid">20573</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Kolobow</surname><given-names>T</given-names></name><name><surname>Tomlinson</surname><given-names>T</given-names></name><name><surname>Iapichino</surname><given-names>G</given-names></name><name><surname>Samaja</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>D</given-names></name><name><surname>Pierce</surname><given-names>J</given-names></name></person-group><article-title>Low-frequency positive pressure ventilation with extracorporeal carbon dioxide removal (LFPPV-ECCO2R): an experimental study</article-title><source>Anesth Analg</source><year>1978</year><volume>57</volume><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1213/00000539-197807000-00018</pub-id><pub-id pub-id-type="pmid">30341</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>JA</given-names></name><name><surname>Gutierrez</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name><name><surname>Allen</surname><given-names>L</given-names></name><name><surname>Dobbs</surname><given-names>L</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.165.2.2108087</pub-id><pub-id pub-id-type="pmid">11790662</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiumello</surname><given-names>D</given-names></name><name><surname>Carlesso</surname><given-names>E</given-names></name><name><surname>Cadringher</surname><given-names>P</given-names></name><name><surname>Caironi</surname><given-names>P</given-names></name><name><surname>Valenza</surname><given-names>F</given-names></name><name><surname>Polli</surname><given-names>F</given-names></name><name><surname>Tallarini</surname><given-names>F</given-names></name><name><surname>Cozzi</surname><given-names>P</given-names></name><name><surname>Cressoni</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Marini</surname><given-names>JJ</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name></person-group><article-title>Lung stress and strain during mechanical ventilation for acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1164/rccm.200710-1589OC</pub-id><pub-id pub-id-type="pmid">18451319</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruhn</surname><given-names>A</given-names></name><name><surname>Bugedo</surname><given-names>D</given-names></name><name><surname>Riquelme</surname><given-names>F</given-names></name><name><surname>Varas</surname><given-names>J</given-names></name><name><surname>Retamal</surname><given-names>J</given-names></name><name><surname>Besa</surname><given-names>C</given-names></name><name><surname>Cabrera</surname><given-names>C</given-names></name><name><surname>Bugedo</surname><given-names>G</given-names></name></person-group><article-title>Tidal volume is a major determinant of cyclic recruitment-derecruitment in acute respiratory distress syndrome</article-title><source>Minerva Anestesiol</source><year>2011</year><volume>77</volume><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">21483386</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caironi</surname><given-names>P</given-names></name><name><surname>Cressoni</surname><given-names>M</given-names></name><name><surname>Chiumello</surname><given-names>D</given-names></name><name><surname>Ranieri</surname><given-names>M</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>SG</given-names></name><name><surname>Cornejo</surname><given-names>R</given-names></name><name><surname>Bugedo</surname><given-names>G</given-names></name><name><surname>Carlesso</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Caspani</surname><given-names>L</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name></person-group><article-title>Lung opening and closing during ventilation of acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1164/rccm.200905-0787OC</pub-id><pub-id pub-id-type="pmid">19910610</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plataki</surname><given-names>M</given-names></name><name><surname>Hubmayr</surname><given-names>RD</given-names></name></person-group><article-title>The physical basis of ventilator-induced lung injury</article-title><source>Expert Rev Respir Med</source><year>2010</year><volume>4</volume><fpage>373</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1586/ers.10.28</pub-id><pub-id pub-id-type="pmid">20524920</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putensen</surname><given-names>C</given-names></name><name><surname>Muders</surname><given-names>T</given-names></name><name><surname>Kreyer</surname><given-names>S</given-names></name><name><surname>Wrigge</surname><given-names>H</given-names></name></person-group><article-title>Lung protective ventilation&#x02014;protective effect of adequate supported spontaneous breathing [article in German]</article-title><source>Anaesthesiol Intensivmed Notfallmed Schmerzther</source><year>2008</year><volume>43</volume><fpage>456</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1081393</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber-Carstens</surname><given-names>S</given-names></name><name><surname>Bercker</surname><given-names>S</given-names></name><name><surname>Hommel</surname><given-names>M</given-names></name><name><surname>Deja</surname><given-names>M</given-names></name><name><surname>MacGuill</surname><given-names>M</given-names></name><name><surname>Dreykluft</surname><given-names>C</given-names></name><name><surname>Kaisers</surname><given-names>U</given-names></name></person-group><article-title>Hypercapnia in late-phase ALI/ADS: providing spontaneous breathing using pumpless extracorporeal lung assist</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>1100</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1426-3</pub-id><pub-id pub-id-type="pmid">19183941</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannidis</surname><given-names>C</given-names></name><name><surname>Lubnow</surname><given-names>M</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Riegger</surname><given-names>GA</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>T</given-names></name></person-group><article-title>Autoregulation of ventilation with neurally adjusted ventilatory assist on extracorporeal lung support</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>2038</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.1007/s00134-010-1982-6</pub-id><pub-id pub-id-type="pmid">20689930</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dembinski</surname><given-names>R</given-names></name><name><surname>Hochhausen</surname><given-names>N</given-names></name><name><surname>Terbeck</surname><given-names>S</given-names></name><name><surname>Uhlig</surname><given-names>S</given-names></name><name><surname>Dassow</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Schachtrupp</surname><given-names>A</given-names></name><name><surname>Henzler</surname><given-names>D</given-names></name><name><surname>Rossaint</surname><given-names>R</given-names></name><name><surname>Kuhlen</surname><given-names>R</given-names></name></person-group><article-title>Pumpless extracorporeal lung assist for protective mechanical ventilation in experimental lung injury</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2359</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000281857.87354.A5</pub-id><pub-id pub-id-type="pmid">17944027</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nierhaus</surname><given-names>A</given-names></name><name><surname>Frings</surname><given-names>DP</given-names></name><name><surname>Braune</surname><given-names>S</given-names></name><name><surname>Baumann</surname><given-names>HJ</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Wittenburg</surname><given-names>B</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name></person-group><article-title>Interventional lung assist enables lung protective mechanical ventilation in acute respiratory distress syndrome</article-title><source>Minerva Anestesiol</source><year>2011</year><volume>77</volume><fpage>797</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">21730927</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Carlesso</surname><given-names>E</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><article-title>Towards ultraprotective mechanical ventilation</article-title><source>Curr Opin Anesthesiol</source><year>2012</year><volume>25</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1097/ACO.0b013e3283503125</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>T</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Luchner</surname><given-names>A</given-names></name><name><surname>Karagiannidis</surname><given-names>C</given-names></name><name><surname>Bein</surname><given-names>T</given-names></name><name><surname>Hilker</surname><given-names>M</given-names></name><name><surname>Rupprecht</surname><given-names>L</given-names></name><name><surname>Langgartner</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Arlt</surname><given-names>M</given-names></name><name><surname>Wenger</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Riegger</surname><given-names>GA</given-names></name><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Lubnow</surname><given-names>M</given-names></name></person-group><article-title>A new miniaturized system for extracorporeal membrane oxygenation in adult respiratory failure</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R205</fpage><pub-id pub-id-type="doi">10.1186/cc8213</pub-id><pub-id pub-id-type="pmid">20017915</pub-id></element-citation></ref></ref-list></back></article>